Acute Promyelocytic Leukemia - Pipeline Review, H1 2012

Global Markets Direct, June 2012, Pages: 60

Acute Promyelocytic Leukemia – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Acute Promyelocytic Leukemia - Pipeline Review, H1 2012', provides an overview of the Acute Promyelocytic Leukemia therapeutic pipeline. This report provides information on the therapeutic development for Acute Promyelocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Promyelocytic Leukemia. 'Acute Promyelocytic Leukemia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Promyelocytic Leukemia.
- A review of the Acute Promyelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Promyelocytic Leukemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acute Promyelocytic Leukemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Promyelocytic Leukemia pipeline depth and focus of Acute Promyelocytic Leukemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Acute Promyelocytic Leukemia Therapeutic Products under Development, Key Players in Acute Promyelocytic Leukemia Therapeutics, Acute Promyelocytic Leukemia Pipeline Overview, Acute Promyelocytic Leukemia Pipeline, Acute Promyelocytic Leukemia Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Promyelocytic Leukemia Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia Therapeutics under Development by Companies
Acute Promyelocytic Leukemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Acute Promyelocytic Leukemia Therapeutics – Products under Development by Companies
Acute Promyelocytic Leukemia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Acute Promyelocytic Leukemia Therapeutics Development
Telik, Inc.
TMRC Co., Ltd.
Acute Promyelocytic Leukemia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
TLK58747 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tamibarotene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clofarabine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tretinoin + Cytarabine + Daunorubicin + Arsenic Trioxide + Gemtuzumab + Methotrexate + Mercaptopurine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tretinoin + Arsenic Trioxide + Idarubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tretinoin + Gemtuzumab Ozogamicin + Arsenic trioxide + Daunomycin + Mercaptopurine + Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tretinoin + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tretinoin + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate + Arsenic Trioxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trisenox + Cytarabine + Idarubicin + Mercaptopurine + Methotrexate + Mitoxantrone Hydrochloride + Tretinoin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
All-Trans Retinoic Acid + Arsenic Trioxide + Idarubicin + Methylprednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lintuzumab + Cytarabine + Idarubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arsenic Trioxide + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate + Tretinoin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
All-Trans Retinoic Acid + Arsenic Trioxide + Idarubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Lintuzumab + Arsenic Trioxide + Idarubicin + Tretinoin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATRA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
p.DOM-WT1-37 DNA Vaccine + p.DOM-WT1-126 DNA Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
All-Trans Retinoic Acid + Arsenic Trioxide + Gemtuzumab Ozogamicin + Methylprednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Promyelocytic Leukemia Therapeutics – Drug Profile Updates
Acute Promyelocytic Leukemia Therapeutics – Discontinued Products
Acute Promyelocytic Leukemia Therapeutics - Dormant Products
Acute Promyelocytic Leukemia – Product Development Milestones
Featured News & Press Releases
Apr 18, 2011: CytRx Announces Publication Of Peer-Reviewed Case Report Documenting Tamibarotene's Successful Elimination Of Recurrent Advanced-Stage Leukemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Acute Promyelocytic Leukemia, H1 2012
Products under Development for Acute Promyelocytic Leukemia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Telik, Inc., H1 2012
TMRC Co., Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Acute Promyelocytic Leukemia Therapeutics – Drug Profile Updates
Acute Promyelocytic Leukemia Therapeutics – Discontinued Products
Acute Promyelocytic Leukemia Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Acute Promyelocytic Leukemia, H1 2012
Products under Development for Acute Promyelocytic Leukemia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012
• Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2012
• Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2013
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2013
• Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2013
• Myelodysplastic Syndrome - Pipeline Review, H1 2012
• Acute Respiratory Distress Syndrome - Pipeline Review, H1 2013
• Acute Myelocytic Leukemia (AML) - Pipeline Review, Q4 2010
• Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2013
• Leukemia Therapeutics Market (2010-2020) (Acute/Chronic lymphocytic leukemia & Acute/Chronic myeloid leukemia) Pipeline forecast & Market forecast in G8 countries